Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride
Brand Names: Mucinex Childrens Multi-Symptom Cold, Amazon Childrens Multi Symptom Cold, Amazon, Aquanaz, Broncomiel, Mucinex Childrens Cough and Congestion
Methodology & AI Transparency ⓘ
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Uses Temporarily relieves common cold symptoms: stuffy nose nasal congestion cough due to minor throat and bronchial irritation helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive
- 2 Real-world patient consensus: 75% patient "Worth It" rating across 14 anonymous logs for Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride (RxNorm RXN-63824949-2112).
- 3 Typical cash cost range: 30-day cash pricing ranges from $12.45 discount cash to $34.50 walk-in retail (NADAC $0.0975/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride include cough (3.8%), application-site irritation (6.5%), nausea (8.7%).
Ask our AI Specialists anything about Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Uses Temporarily relieves common cold symptoms: stuffy nose nasal congestion cough due to minor throat and bronchial irritation helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride operates pharmacologically within the Expectorant class (RxNorm RXN-63824949-2112; NDC 63824-949, 55758-520), engaging target pathways across 5 mg/5mL / 100 mg/5mL Solution; 18 mg/15mL / 200 mg/15mL Liquid dosing.
Systemic exposure to Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride reflects F ≈ 60%–72% systemic availability after standard oral Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride administration absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride regimens, sustaining receptor engagement across a Terminal t½ estimated at 4–8 hrs depending on renal/hepatic reserve (Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride) half-life window (time to peak concentration spans 1 to 4 hrs under dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride maintenance response profile).
Dosing protocols (5 mg/5mL / 100 mg/5mL Solution or 18 mg/15mL / 200 mg/15mL Liquid or 15 mg/1 / 400 mg/1 Tablet or 200 mg/10mL / 10 mg/10mL Syrup or 5 mg/5mL / 100 mg/5mL Suspension) balance efficacy (75.00% patient satisfaction across 14 logs) against nausea (8.7% of reports), headache (8.3% of reports), dizziness (6.8% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride or dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-06-23 dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride spl.
Avoid overlapping expectorant prescriptions alongside Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride or Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-06-23 Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride SPL
Logged Side-Effect Incidence (14 Reports)
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With: What a 327-Participant Study Found Conclusions: In this phase 3 trial in patients with MDD, treatment with dextromethorphan-bupropion (AXS-05) resulted in significant improvements in depressive symptoms compared to placebo starting 1 week after treatment... The Journal of clinical psychiatry • 2022-05-30 • Phase III Randomized Trial | N = 327 | 93/100 | PMID 35649167 ↗ |
| What the Latest Evidence Really Says About Benefits and safety of dextromethorphan-bupropion combination (AXS-05) in the 64.6% for Bupropion), the combination's safety profile remained comparable, with no significant increase in treatment discontinuation. Indian journal of pharmacology • 2025-07-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 40686359 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of AXS-05 (Dextromethorphan-Bupropion) in depression: A Randomized In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated. The American journal of psychiatry • 2022-07-15 • Randomized Controlled Trial | N = 43 | 88/100 | PMID 35582785 ↗ |
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0975/unit (~$2.93/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $12.45 / mo | View logs ↓ |
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride RxNorm Concept ID | RXN-63824949-2112 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0975 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.45 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride: FDA labeling (2026-06-23, NDC 63824-949), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.